Arbutus Biopharma Corp financial data

Symbol
ABUS on Nasdaq
Location
Warminster, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 983% % 51%
Debt-to-equity 33% % 3.8%
Return On Equity -50% % 26%
Return On Assets -38% % 27%
Operating Margin -320% % 74%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 192,324,017 shares 1.5%
Common Stock, Shares, Outstanding 191,953,665 shares 1.3%
Entity Public Float $454,399,613 USD 58%
Common Stock, Value, Issued $1,418,560,000 USD 0.78%
Weighted Average Number of Shares Outstanding, Basic 191,778,950 shares 1.5%
Weighted Average Number of Shares Outstanding, Diluted 191,778,950 shares 1.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $14,606,000 USD 117%
Research and Development Expense $29,045,000 USD -54%
General and Administrative Expense $16,916,000 USD -25%
Operating Income (Loss) $46,803,000 USD 44%
Nonoperating Income (Expense) $4,526,000 USD -30%
Net Income (Loss) Attributable to Parent $42,277,000 USD 45%
Earnings Per Share, Basic -0.23 USD/shares 47%
Earnings Per Share, Diluted -0.23 USD/shares 47%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $22,408,000 USD -30%
Cash, Cash Equivalents, and Short-term Investments $122,600,000 USD -7.3%
Accounts Receivable, after Allowance for Credit Loss, Current $905,000 USD -44%
Assets, Current $97,442,000 USD -27%
Property, Plant and Equipment, Net $137,000 USD -96%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $131,000 USD
Assets $97,710,000 USD -30%
Liabilities, Current $5,184,000 USD -73%
Operating Lease, Liability, Noncurrent $391,000 USD -60%
Liabilities $20,311,000 USD -39%
Accumulated Other Comprehensive Income (Loss), Net of Tax $48,129,000 USD -0.08%
Retained Earnings (Accumulated Deficit) $1,376,317,000 USD -3.2%
Stockholders' Equity Attributable to Parent $77,399,000 USD -28%
Liabilities and Equity $97,710,000 USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $13,391,000 USD 31%
Net Cash Provided by (Used in) Financing Activities $2,784,000 USD -89%
Net Cash Provided by (Used in) Investing Activities $11,349,000 USD -3%
Common Stock, Shares, Issued 191,953,665 shares 1.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $746,000 USD -96%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $22,408,000 USD -30%
Deferred Tax Assets, Valuation Allowance $175,426,000 USD 7.2%
Operating Lease, Liability $1,289,000 USD -27%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $42,316,000 USD 44%
Lessee, Operating Lease, Liability, to be Paid $1,422,000 USD -30%
Property, Plant and Equipment, Gross $16,305,000 USD -1.6%
Operating Lease, Liability, Current $531,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $654,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $634,000 USD 2.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $133,000 USD -51%
Lessee, Operating Lease, Liability, to be Paid, Year Three $134,000 USD -80%
Deferred Tax Assets, Operating Loss Carryforwards $96,075,000 USD 7.8%
Preferred Stock, Shares Authorized 1,164,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $0 USD -100%
Additional Paid in Capital $83,285,000 USD 2.3%
Depreciation, Depletion and Amortization $330,000 USD -7%
Share-based Payment Arrangement, Expense $4,891,000 USD -46%
Interest Expense $168,000 USD -85%